NeOnc Technologies Holdings Stock (NASDAQ:NTHI)

Ownership Financials Chart

Previous Close

$4.49

52W Range

$3.69 - $12.99

50D Avg

$4.83

200D Avg

$7.79

Market Cap

$89.78M

Avg Vol (3M)

$92.13K

Beta

0.29

Div Yield

-

NTHI Company Profile

Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Mar 26, 2025

Website

NTHI Performance

NTHI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$83.00K	$70.46K	$20.00K
Operating Income	$-7.14M	$-12.20M	$-2.84M
Net Income	$-11.90M	$-14.92M	$-3.05M
EBITDA	$-9.10M	$-12.20M	$-2.85M
Basic EPS	$-0.63	$-0.80	$-0.16
Diluted EPS	$-0.63	$-0.80	$-0.16

Fiscal year ends in Dec 24 | Currency in USD